-- 香港証券取引所に木曜日に提出された書類によると、ジョルダーノ・インターナショナル(香港証券取引所:0709)は、第1四半期の売上高が前年同期の9億9,700万香港ドルから3.9%増の10億4,000万香港ドルとなったと発表した。 中華圏の売上高は7.8%増の4億5,600万香港ドル、東南アジアとオーストラリアの売上高は4.2%増の3億9,800万香港ドルとなった。湾岸協力会議(GCC)地域の売上高は5.2%減の1億8,200万香港ドルだった。 販売チャネル別に見ると、オンライン売上高は前年同期比40.5%増の1億6,300万香港ドル、オフライン売上高は2.3%増の7億6,700万香港ドルだった。 フランチャイズ加盟店への卸売売上高は19%減の1億600万香港ドルだった。 グループ全体の既存店売上高は8.2%増の8億1,700万香港ドルとなり、前年同期の7億5,500万香港ドルから増加した。 3月31日時点で、このアパレル小売業者は1,565店舗を運営しており、前年同期の1,720店舗から減少した。
Related Articles
Oneview Healthcare Reports Decline in Q1 Cash Receipts From Customers; Shares Up 3%
Oneview Healthcare (ASX:ONE) reported cash receipts from customers of about 3.3 million euros for the first quarter, compared with 4.2 million euros a year earlier, according to a Monday filing with the Australian bourse.The company noted that the year-ago figure includes two large customer receipts totaling more than 2 million euros, which were due to be received during the fourth quarter of 2024 but were received in early 2025.Oneview Healthcare ended March with a cash balance of AU$17.1 million, up from AU$8.1 million at the close of 2025, per the filing.The company's shares gained 3% in recent Monday trade.
Paradigm to Advance Participants Through Day 112 Follow-Up Period in Phase Three Knee Osteoarthritis Trial, Shares Reach One-Year Low
Paradigm Biopharmaceuticals (ASX:PAR) is set to progress participants through the day 112 follow-up period for the phase three trial evaluating injectable pentosan polysulfate sodium for the treatment of pain associated with knee osteoarthritis in the June quarter, which is required for inclusion in the interim analysis dataset, according to a Monday Australian bourse filing.The independent statistical analysis results for the data set are expected around August. Timing remains subject to the scheduling and review processes of independent third parties, and there is a reasonable likelihood that final interim outcomes may extend into September, it cautioned.The interim analysis is expected to provide the first phase three evaluation of efficacy and safety for injectable pentosan polysulfate sodium in knee osteoarthritis. Primary endpoint top-line results are expected in the March 2027 quarter.Its shares fell 14% in recent trading on Monday, reaching their lowest point in over a year.
Sanan Optoelectronics Q1 Profit Down 68%, Revenue Slides 33%
Sanan Optoelectronics (SHA:600703) posted first-quarter attributable net profit of 67.5 million yuan, down 68% from 211.9 million yuan the previous year.Earnings per share declined to 0.01 yuan from 0.04 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue declined 33% year over year to 2.91 billion yuan from 4.31 billion yuan.Shares of the software company declined 2% in recent trade.